A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe
journal contributionposted on 2020-09-03, 10:07 authored by S Seidu, X Cos, S Brunton, SB Harris, SPO Jansson, M Mata-Cases, AMJ Neijens, P Topsever, Kamlesh Khunti
Type 2 diabetes and its associated comorbidities are growing more prevalent, and the complexity of optimising glycaemic control is increasing, especially on the frontlines of patient care. In many countries, most patients with type 2 diabetes are managed in a primary care setting. However, primary healthcare professionals face the challenge of the growing plethora of available treatment options for managing hyperglycaemia, leading to difficultly in making treatment decisions and contributing to therapeutic inertia. This position statement offers a simple and patient-centred clinical decision-making model with practical treatment recommendations that can be widely implemented by primary care clinicians worldwide through shared-decision conversations with their patients. It highlights the importance of managing cardiovascular disease and elevated cardiovascular risk in people with type 2 diabetes and aims to provide innovative risk stratification and treatment strategies that connect patients with the most effective care.
CitationPrimary Care Diabetes, 2020, https://doi.org/10.1016/j.pcd.2020.05.004
Author affiliationDiabetes Research Centre, College of Life Sciences
- AM (Accepted Manuscript)